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Numerous concerns have emerged regarding the dangers of extended benzodiazepine use and 
abuse, as well as continued prescribing by medical professionals despite related 
contraindications. Primary care physicians (PCPs) may find decisions around benzodiazepine 
prescription and related patient encounters to be especially challenging. Little is known on the 
efficacy of routine medical training and supervision/consultation models in preparing emerging 
PCPs for managing the dilemmas that may ensue with regards to prescribing benzodiazepines. 
The present study sought to begin addressing this gap by conducting an initial qualitative inquiry 
into the training and supervision experiences and needs of a group of current family medicine 
residents. A 30-minute semi-structured focus group interview (consisting of four participants) 
was conducted via video. Two main themes, Variability in Resources and Supports and  
Patient–Provider Interactions, were identified through thematic analysis. Participants highlighted 
concerns that inconsistencies in resources and supervisory approaches to benzodiazepines might 
adversely impact their therapeutic relationship with patients, and an initial hypothesis regarding 
this possible association was presented for further research. Participants identified increased 
empathy from supervisors around this concern as a primary area of need for future support. 
Limitations of the study, implications for practice, and future directions for research were 
discussed. The present study found that a better understanding of the early training and 
supervision experiences of emerging primary care providers around benzodiazepines will be 
critical in supporting the next generation of providers, improving patient care, and shaping future 
prescribing practices related to this difficult class of medications. 
This dissertation is available in open access at AURA, http://aura.antioch.edu/  
and Ohio Link ETD Center, https://etd.ohiolink.edu/.  
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Physician Training and Support in Managing Dilemmas Around Benzodiazepine Prescribing 
On September 23, 2020, the U.S. Food and Drug Administration (FDA) announced that it 
would require an update to the Boxed Warning label on benzodiazepine prescriptions to include 
the risks of misuse, abuse, physical dependence, addiction, and withdrawal (U.S. Food and Drug 
Administration, 2020). This reflected a number of growing concerns regarding this widely used 
class of psychotropic medication. In 2019, an estimated 92 million benzodiazepine prescriptions 
were dispensed from U.S. outpatient pharmacies (U.S. Food and Drug Administration, 2020). 
Around 5% of U.S. adults ages 18 through 80 (over 10 million individuals) were estimated to 
receive one or more benzodiazepine prescriptions in 2008 (Olfson, King, & Schoenbaum, 2015). 
A 2019 cross-sectional study, conducted using data from the National Survey on Drug Use and 
Health Data, revealed that recent numbers may be significantly higher than previous estimates, 
with over 30.6 million U.S. adults reporting (prescription and non-prescription) use of one or 
more benzodiazepines between 2015 and 2016 (Maust, Lin, & Blow, 2019). Additional 
longitudinal data collected between 2003 and 2015 support a steady increase in the number of 
benzodiazepine prescriptions issued in outpatient settings over the past decade, particularly by 
non-psychiatric providers (Agarwal & Landon, 2019).  
Growing Concerns Around Benzodiazepines 
Benzodiazepines are one of the most frequently misused and abused types of prescription 
medications. Maust et al. (2019) found that nearly 20% of reported cases of benzodiazepine use 
between 2015 and 2016 could be classified as misuse (e.g., using without a prescription, taking 
different doses than prescribed). These medications have a high potential for dependence and 
addiction due to their ability to produce almost immediate sedative and euphoric effects (Brett & 
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Murnion, 2015; Siriwardena, 2017). In 2011, over 500,000 (one half million) emergency 
department (ED) visits occurred in relation to benzodiazepine use (Substance Abuse and Mental 
Health Services Administration, 2013). Seventy-nine percent of these visits were related to  
non-medical use, and 24.2% of these visits involved co-occurring alcohol consumption (Olfson 
et al., 2015). These ED admission statistics represented an approximate 154% increase from 
2004 numbers, illustrating a growing problem of benzodiazepine-related physical and mental 
health emergencies (Substance Abuse and Mental Health Services Administration, 2013).  
 A number of dangers have been linked to prolonged and/or excessive benzodiazepine 
use, including a) drowsiness, confusion, and motor impairments (Authier et al., 2009; Brett & 
Murnion, 2015; Landry, Smith, McDuff, & Baughman, 1992); (b) potentially enduring deficits in 
a number of cognitive abilities (Crowe & Stranks, 2017); and (c) an increase in psychiatric 
symptoms related to depression and anxiety (Brunette, Noordsy, Xie, & Drake, 2003; Jones, 
Nielsen, Bruno, Frei, & Lubman, 2011). Benzodiazepines are one of the most commonly 
encountered drugs in overdose-related deaths, frequently found in combination with opioids and 
alcohol (Olfson et al., 2015). A growing body of research supports that chronic benzodiazepine 
use may be especially dangerous in the elderly population, with psychomotor impairments 
resulting in an increased likelihood of falls (Pariente et al., 2008) and possible memory 
impairments. A possible link between benzodiazepine use in the elderly and dementia is 
currently under investigation (Billioti de Gage et al., 2012; Markota, Rummans, Bostwick, & 
Lapid, 2016; Opondo et al., 2012).  
 In addition to the number of potentially adverse side effects associated with long-term 
benzodiazepine use, the process of withdrawal (particularly when use is abruptly stopped) can 
induce many unpleasant and potentially life-threatening physical and psychological symptoms 
         
  
4 
including catatonia, seizures, extreme anxiety (Fixsen & Ridge, 2017), dysphoria (Baandrup, 
Fagerlund, & Glenthoj, 2017), and even psychotic experiences (Brett & Murnion, 2015; Morales 
et al., 2017). These symptoms can severely limit an individual’s ability to function in a number 
of everyday situations (Fixsen & Ridge, 2017) and may also increase the likelihood of 
developing and/or acting on suicidal thoughts (Dodds, 2017), engaging in other impulsive or 
self-endangering behaviors (Authier et al., 2009), or directing aggression toward others (Jones et 
al., 2011). 
Inappropriate Benzodiazepine Prescription Practices Persist 
 Given their relatively high potential for misuse, abuse, and psychological and physical 
dependence, and their host of dangerous side effects and withdrawal symptoms, benzodiazepines 
require close medical monitoring. The majority of benzodiazepine prescriptions appear to be 
managed by non-psychiatric practitioners (Olfson et al., 2015). Within recent years, many 
psychotropic medications, including benzodiazepines, have been increasingly prescribed and 
followed by primary care physicians (PCPs; Hedenrud, Svensson, & Wallerstedt, 2013). 
Concerns have arisen with regards to the abilities of PCPs to manage these medications, 
particularly in psychiatrically complex patients who may require a number of psychotropic 
medications (Ballester, Filippon, Braga, & Andreoli, 2005). Additionally, despite recent 
adjustments in recommended best practices around the use of benzodiazepines in the treatment 
of anxiety (Baldwin et al., 2005) and insomnia (Morgenthaler et al., 2007; Schutte-Rodin, Broch, 
Buysse, Dorsey, & Sateia, 2008), and cautions against their use in elderly patients, a 
considerable number of new prescriptions appear to be inappropriately issued on a regular basis 
(Cloos & Ferreira, 2009; Opondo et al., 2012; Siriwardena, 2017).  
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Providers Face Dilemmas Around Prescribing Benzodiazepines 
Research suggests that medical providers face a number of ethical, personal, and 
interpersonal dilemmas when asked by a patient to begin a new benzodiazepine prescription or to 
continue benzodiazepine treatment initiated by another professional (Anthierens, Habraken, 
Petrovic, & Christiaens, 2007; Bradley, 1992a; Siriwardena, Qureshi, Gibson, Collier, & 
Latham, 2006). Face-to-face encounters around these medication requests may be rife with a 
number of difficult interactions on both patient (Fixsen & Ridge, 2017) and provider (Anthierens 
et al., 2007; Bendtsen, Hensing, McKenzie, & Stridsman, 1999; Bradley, 1992a) ends. Literature 
around both broad medication issues (Upshur, Bacigalupe, & Luckmann, 2010) as well as 
benzodiazepine medications in particular (Iliffe et al., 2004; Mah & Upshur, 2002) suggest that 
significant gaps frequently exist between patient and provider understanding, preferences, 
intentions, and concerns within these encounters.  
In recent years there has been an increasing emphasis on building interpersonal and social 
communication competencies in medical trainees (Batalden, Leach, Swing, Dreyfus, & Dreyfus, 
2002). However, training programs appear to be highly variable with regards to how they 
implement curricula around these competencies (Cape, Hannah, & Sellman, 2006; Kelleher, 
2007). There does not appear to be any recent research on the firsthand experiences of medical 
practitioners regarding the effectiveness of their training in preparing them to manage 
challenging encounters around controlled psychotropic substances (such as benzodiazepines) in 
actual practice. The present study sought to begin filling this gap by investigating the subjective 
experiences of a group of emerging medical professionals (family medicine residents) with 
regards to training, supervision, and consultation around benzodiazepines.  
 




The Rise of Benzodiazepines 
Benzodiazepines are a group of sedative hypnotic medications typically prescribed for 
the treatment of acute anxiety and panic symptoms, as well as insomnia. In addition to offering 
anxiolytic benefits, benzodiazepines may also be used in medicine for their anticonvulsant, 
muscle relaxant, and anesthetic effects (Julien, 2013). Commonly prescribed benzodiazepines 
include short-acting agents, such as alprazolam (Xanax), triazolam (Halcion), and midazolam 
(Versed); intermediate-acting agents, such as lorazepam (Ativan) and clonazepam (Klonopin); 
and longer-acting agents, such as diazepam (Valium). Benzodiazepines first emerged in the 
1960s as an alternative to the prevailing barbiturate drugs of the time, such as amobarbital 
(Wick, 2013). Due to their relative safety in comparison to these former drugs, benzodiazepines 
subsequently experienced a surge in popularity. In 2013, alprazolam was the number one most 
prescribed psychotropic medication in the United States; this represented a stable trend from 
previous years (Grohol, 2018). Another benzodiazepine, lorazepam, was similarly high on the 
list, ranking as the fifth most frequently prescribed psychotropic in 2013, with over 28 million 
prescriptions issued (Grohol, 2018). Per CDC estimates, benzodiazepines were prescribed at an 
overall national average of 37.6 prescriptions per 100 individuals in 2012 (Paulozzi, Mack, & 
Hockenberry, 2014). Frequency of benzodiazepine prescription appears to be highly variable 
across states, with Southern states such as Alabama, Tennessee, and West Virginia exhibiting 
higher prescribing rates than others (Paulozzi et al., 2014). Maust, Lin, Blow, and Marcus (2018) 
analyzed state and county-wide benzodiazepine prescription data across the U.S. from the 2015 
Medicare Public Use Files (PUF). Counties with lower median income levels, lower levels of 
educational attainment, and higher rates of opioid prescriptions were associated with higher 
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numbers of benzodiazepine prescriptions, even after adjustments were made regarding 
availability of mental health resources (Maust et al., 2018).  
Long-term benzodiazepine use appears to be more frequent in females than in males, 
though a considerable proportion of illicit use may be attributed to males (Olfson et al., 2015). 
Individuals with existing mental health and substance use histories may be more likely to 
develop dependence and/or engage in benzodiazepine misuse (Baandrup et al., 2017; Brunette et 
al., 2003). Additionally, socioeconomic factors have been implicated in long-term 
benzodiazepine use (Morales-Suarez-Varela, Jaen-Martinez, Llopis-Gonzalez, & Sobrecases, 
1997), with users citing a desire to escape from overwhelming life stressors (Fixsen & Ridge, 
2017).  
Risks Associated with Prolonged Use 
Benzodiazepines act by enhancing the binding capacity of gamma-aminobutyric acid 
(GABA), a key neurotransmitter involved in inhibitory responses of the central nervous system, 
to its cellular receptor (Campo‐Soria, Chang, & Weiss, 2006; Julien, 2013). This can promote 
perceptions of physical relaxation and a sense of subjective wellbeing.  
Despite their assumed safety in comparison to previous sedative hypnotic medications, 
and their seemingly therapeutic short-term effects, a growing body of research suggests that 
benzodiazepines may pose a number of unexpected risks with long-term use. High doses of 
benzodiazepines may cause paradoxical agitation in the forms of elevated anxiety, irritability, 
hostility, and aggression (Julien, 2013). Crowe and Stranks (2017) conducted a meta-analysis on 
the relationship between extended benzodiazepine use and various cognitive abilities and found 
statistically significant adverse effects on working memory, visuospatial construction, divided 
attention, and more general sustained attention in benzodiazepine users. Some of these cognitive 
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challenges appeared to persist even after withdrawal and sustained abstinence (Crowe & Stranks, 
2017). These deficits may adversely impact learning and related school and work performance in 
children and adults (Julien, 2013).  
Results from two large cohort studies in France and the United Kingdom found all-cause 
mortality to be significantly higher in benzodiazepine users (as well as those who used both 
benzodiazepines and antidepressants) than those who used neither medication across a 12-month 
time period (Palmaro, Dupouy, & Lapeyre-Mestre, 2015). Additional studies have observed a 
potential association between benzodiazepine use and risk of premature mortality, though more 
research is warranted regarding causality (Charlson, Degenhardt, McLaren, Hall, & Lynskey, 
2009). Many mediating variables may play a role in mortality and overall health, including 
number of adverse childhood experiences (ACEs), which appears to be associated with a higher 
likelihood of being prescribed one or more psychotropic medications (Anda et al., 2007). It is 
therefore possible that patients with other risk factors for premature mortality may be more likely 
to be prescribed benzodiazepines and other medications. Research has also demonstrated that 
individuals who use benzodiazepines may be at an increased risk for suicidal ideation and 
attempts, particularly during withdrawal (Dodds, 2017; Jones et al., 2011). 
Long-term use of benzodiazepines is prevalent (Neutel, 2005). Physical and 
psychological dependence may develop within less than one month of regular benzodiazepine 
use, even at established therapeutic doses (Authier et al., 2009; Julien, 2013). Unpleasant 
withdrawal symptoms may develop after only two weeks of regular use (Brett & Murnion, 
2015). Individuals may endorse fear of withdrawal effects as a primary motivation for continued 
benzodiazepine use, even when the medications are only minimally helpful (Barter & Cormack, 
1996). Physical symptoms of withdrawal may include tachycardia, hypertension, tremors, chest 
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pain, convulsions (Brett & Murnion, 2015; Schweizer & Rickels, 1998; Tyrer, Murphy, & Riley, 
1990) and potentially life-threatening catatonia (Deuschle & Lederbogen, 2001). Psychological 
symptoms may include: (a) feelings of dread, overwhelming panic, exaggerated anxiety, 
paranoia (Aguiluz, Alvarez, Pimentel, Abarca, & Moore, 2018; Fixsen & Ridge, 2017);  
(b) intrusive thoughts (Baandrup, Fagerlund, & Glenthoj, 2017); (c) extreme sensitivity to 
various sensory stimuli (Authier et al., 2009); (d) depression (Baandrup et al., 2017);  
(e) insomnia (Tyrer, Murphy, & Riley, 1990); (f) nightmares, personality changes, irritability 
(Aguiluz et al., 2018; Schweizer & Rickels, 1998); (g) aggression (Jones et al., 2011); and  
(h) perceptual disturbances (Brett & Murnion, 2015; Martin-Kleisch & Zulfiqar, 2017). In severe 
cases, individuals may meet the full diagnostic criteria for mania and/or psychosis (Morales et 
al., 2017). Firsthand accounts from individuals struggling with withdrawal have also described 
extreme feelings of depersonalization, derealization, and feelings of alienation and isolation from 
the world (Brett & Murnion, 2015; Fixsen & Ridge, 2017). Medical decisions regarding whether 
to continue benzodiazepine prescriptions, even when discontinuation may be clinically 
appropriate, are complicated by the many potential dangers of withdrawal syndrome. Physicians 
are advised to discontinue benzodiazepine medications with caution, through a gradual tapering 
process (Aguiluz et al., 2018; Landry et al., 1992). 
Changing Recommendations for Prescribing Benzodiazepines 
Due to established concerns about various adverse health effects and the dangers of 
withdrawal, numerous guidelines have been issued advocating that benzodiazepine prescription 
be limited to a maximum of two to four weeks and to only the most severe circumstances 
(Benzodiazepine Committee, 2002; Janhsen, Roser, & Hoffmann, 2015; Salzman, 1991). 
Additionally, while benzodiazepines were formerly indicated in the treatment of anxiety and 
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insomnia, pharmacological recommendations around these conditions have shifted following 
extensive research on alternative best practices. For anxiety disorders, which are frequently 
chronic conditions, selective serotonin reuptake inhibitors (SSRIs) are now the recommended 
frontline psychotropic intervention (Baldwin et al., 2005). Though the therapeutic effects of 
SSRI medications tend to have a longer latency period (taking anywhere from two weeks to two 
months to take full effect) than benzodiazepines (which offer individuals immediate relief), they 
are believed to be a more efficacious treatment in the long term, and discontinuation of SSRIs 
appears to be associated with fewer adverse side effects (Offidani, Guidi, Tomba, & Fava, 2013). 
Additionally, psychotherapeutic or behavioral interventions (particularly in the form of cognitive 
behavioral therapy [CBT]) have been demonstrated to be as effective as pharmacological 
treatments for anxiety, and, in combination with medication, may offer an individual the most 
lasting reduction in symptoms (Roy-Byrne et al., 2010). For the treatment of insomnia, 
behavioral interventions are increasingly advocated as a first line of intervention before 
beginning treatment with medication (Morgenthaler et al., 2007; Schutte-Rodin et al., 2008). 
Alternative sleep medications known as “Z-drugs” (such as zolpidem) are being increasingly 
explored (Lieberman, 2007), though, similar to benzodiazepines, concerns have emerged 
regarding their tolerability and safety in cases of long-term use (Siriwardena et al., 2006). 
Increasing Benzodiazepine Management in Primary Care 
Despite established changes in best practices, new benzodiazepine prescriptions continue 
to be issued at an increasing rate (Anderson, Stowasser, Freeman, & Scott, 2014; Cloos & 
Ferreira, 2009; Siriwardena, 2017). Additionally, a number of prescriptions continue to be issued 
for elderly patients, despite the growing literature on this age group’s particular vulnerability to 
adverse benzodiazepine-associated effects (Olfson et al., 2015; Opondo et al., 2012). Gerlach, 
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Maust, Leong, Mavandadi, and Oslin (2018) investigated the transition to long-term 
benzodiazepine use in a sample of 576 older adult patients who had been issued new 
prescriptions by non-psychiatric prescribers between 2008 and 2016; results showed that over 
26% of these patients met criteria for long-term use. Medication decisions around extended 
prescriptions were not predicted by higher anxiety or depression levels as the researchers had 
anticipated (Gerlach et al., 2018).  
In recent years, due to relative shortages of psychiatric professionals, benzodiazepine 
prescriptions have become increasingly managed by non-psychiatric providers, such as primary 
care providers (PCPs). This setting has been associated with some of the more problematic 
prescribing practices (Mugunthan, McGuire, & Glasziou, 2011; Rutkow, Turner, Lucas, Hwang, 
& Alexander, 2015; Siriwardena et al., 2010). PCPs are increasingly confronted with patient 
requests for new or continued benzodiazepine prescriptions. In some cases, they may be asked by 
patients to begin a new medication for experiences of overwhelming anxiety, panic, and/or 
insomnia (Johnson & Longo, 1998; Linden, Bär, & Geiselmann, 1998). Some patients may 
endorse previous benzodiazepine use (as prescribed or illicitly) and observed benefits. 
Additionally, patients may have been prescribed a benzodiazepine medication (either short term 
or long term) by another provider (in Primary Care, following an ED admission, following a stay 
in an inpatient psychiatric setting, etc.) and may require a refill. Though patients may have been 
issued an initial benzodiazepine prescription by one medical professional, they may not be 
followed by that provider long term. Therefore, the PCP is often the de facto provider expected 
to make further decisions regarding continuation or discontinuation of this prescription (Zandstra 
et al., 2004). This can place PCPs in a difficult position where they must weigh the costs and 
benefits of various treatment options and negotiate them with the patient.  
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Provider Dilemmas Around Prescribing Benzodiazepines 
PCPs may endorse particular ambivalence and discomfort in making decisions around 
prescribing benzodiazepines, characterizing these experiences as dilemmas (Bradley, 1992a; 
Marienfeld, Tek, Diaz, Schottenfeld, & Chawarski, 2012; Wain, Khong, & Sim, 2007). The 
well-known dangers of both extended benzodiazepine use and discontinuation are apt to 
make decision-making around medication maintenance or adjustment particularly 
challenging for physicians. Bendtsen et al. (1999) conducted a phenomenological critical 
incident study on the quality of dilemmas encountered by 213 Swedish general practitioners 
(GPs) regarding patient requests for benzodiazepine prescriptions and found a number of salient 
themes. Dilemmas around concern for the wellbeing of patients, integrity of the physician being 
compromised during decision-making, limited time for individual visits, and difficulties trusting 
the patient to appropriately handle medications were reported. Major consequences of dilemmas 
included damage to the patient–provider relationship or prescribing benzodiazepines in haste due 
to time limitations. The authors made recommendations for increased training in communication 
and negotiation skills, as well as more time with individual patients (Bendtsen et al., 1999). 
These findings built upon the earlier work of Bradley (1992b) in English GPs, which explored 
more general themes related to provider discomfort around medications (psychotropic and non-
psychotropic). Some of the most frequent themes included (a) concerns around drug toxicity, 
(b) failure to live up to own expectations, (c) concerns about the appropriateness of treatment,  
(d) ignorance/uncertainty about management, and (e) concerns about negative patient evaluation 
(Bradley, 1992b).  
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Numerous Variables Influence Prescribing Practices of Providers 
A number of variables have been shown to influence the more general prescribing 
decisions of providers. Patient demographic variables such as (a) age (Bradley, 1992a; Hedenrud 
et al., 2013), (b) gender (Bradley, 1992b), (c) race and ethnicity (Burgess, Van Ryn,  
Crowley-Matoka, & Malat, 2006), (d) socioeconomic status (Bradley, 1992a), and (e) education 
level (Cook, Marshall, Masci, & Coyne, 2007) may play a role. Perceptions or assumptions 
regarding patient needs, abilities to function, and severity of social stressors may play a role in 
decision-making around prescribing psychotropic medications (Hedenrud et al., 2013; Rogers et 
al., 2007; Šubelj, Vidmar, & Švab, 2010). Evidence for previous or ongoing substance use or 
abuse serves as a common deterrent for prescribing benzodiazepines (Bendtsen et al., 1999; 
Marienfeld et al., 2012). Friends and family members may affect patient motivations and beliefs 
around benzodiazepines, as well as provider concerns about potential risks and benefits of 
prescribing (Hedenrud et al., 2013). Patient expectations of a medication (Hedenrud et al., 2013) 
and seeming responsibility (Dybwad, Kjølsrød, Eskerud, & Laerum, 1997) may also affect 
providers’ prescribing decisions. 
A number of provider variables have also been shown to play a role in guiding decisions 
around benzodiazepine prescription, including provider knowledge and comfort regarding 
psychotropic medications and mental health (Hedenrud et al., 2013; Sirdifield et al., 2013) and 
ability to manage uncertainty or complexity (Cook et al, 2007; Siriwardena et al., 2010). 
Additionally, provider feelings of self-efficacy, confidence, assertiveness, and comfort with 
negotiating (Anderson et al., 2014; Hedenrud et al., 2013) may impact his perceived ability to 
comply with or challenge patient requests. Specific to self-efficacy, additional variables related 
to provider skills, attitudes, influence, and overall support within an organization may be 
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relevant; providers who are lacking in knowledge and practice may still feel confident and 
effective within their role through the buffering influence of colleagues or other supports 
(Anderson et al., 2014). PCPs may experience concerns about boundaries between primary care 
and other prescribing contexts and may worry about how their behaviors will influence relations 
with colleagues (Anderson et al., 2014; Hedenrud et al., 2013). Ethically, providers may feel a 
sense of professional responsibility or obligation to make appropriate decisions regarding risk 
management and harm reduction (Rogers et al., 2007). PCPs may experience fewer concerns 
around addiction in older adults and may be more likely to associate continuation of 
benzodiazepines with compassionate treatment and discontinuation of these medications with 
harsh treatment (Cook et al., 2007). Personal use of benzodiazepines may also influence provider 
decisions around patient prescriptions (Linden & Gothe, 1998; Srisurapanont, Garner, Critchley, 
& Wongpakaran, 2005). 
In addition to a number of individual patient and provider variables, several  
patient–provider relationship variables appear to factor into encounters surrounding 
benzodiazepine medication management. Familiarity with a patient and related trust (Dybwad et 
al., 1997; Marienfeld et al., 2012; Wain et al., 2007), desire to maintain a good patient–provider 
relationship (Wain et al., 2007), and fear of patient dissatisfaction and/or resistance (Bendtsen et 
al., 1999; Cook et al., 2007) may persuade providers to comply with patient requests for 
benzodiazepine prescriptions. Previous interpersonal experiences with other patients regarding 
benzodiazepine requests may also influence provider decision-making (Parr, Kavanagh, Young, 
& McCafferty, 2006). Psychiatrists identified feeling manipulated or deceived by a patient as a 
common reason for refusing benzodiazepine prescriptions (Marienfeld et al., 2012). These 
characteristics were associated with greater concern for potential misuse/abuse down the line or 
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diversion to other individuals within the household (Marienfeld et al., 2012). Additionally, 
overall ease of communication (which encompasses both provider and patient abilities) may play 
a substantial role in the outcomes of encounters regarding medication requests (Bradley, 1992b; 
Cook et al., 2007; Hedenrud et al., 2013). Gaps in knowledge, understanding, preferences, and 
communication between patients and providers are common and may create additional tensions 
(Iliffe et al., 2004; Mah & Upshur, 2002; Parr et al., 2006).  
Finally, variables related to broader workplace context and additional societal and 
cultural concerns may emerge in benzodiazepine-related medical encounters. Workplace 
constraints such as time, money, technology (Anderson et al., 2014; Hedenrud et al., 2013), and 
workload (Šubelj et al., 2010) may affect providers’ comfort, willingness, and abilities to 
prescribe a number of medications, including benzodiazepines. Media may impact patient 
knowledge and perceptions of certain medications (Hedenrud et al., 2013). Additionally, broader 
regional guidelines for prescribing practices, as well as pharmacological companies, may 
influence provider responsibilities and related decision-making (Hedenrud et al., 2013). 
Research Gaps and Purpose of Current Study 
Given the high incidence of benzodiazepine-related medical and mental health 
emergencies, growing research findings on the potential dangers that both extended use and 
withdrawal may pose, and continually high rates of inappropriate prescribing practices, there is a 
clear need for continued support of both patients and providers around these issues. The bulk of 
existing literature on provider difficulties around prescribing benzodiazepines appears to focus 
on the experiences of established medical providers. However, broader research suggests that 
emerging medical professionals (medical residents) frequently lack confidence in their clinical 
abilities to manage patient requests for possible drugs of dependence and may be particularly 
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vulnerable to stress and distress with regards to these issues (Ballester et al., 2005; Hedenrud et 
al., 2013; Taverner, Dodding, & White, 2000). With controlled substances, such as 
benzodiazepines, which have a high potential for misuse, abuse, and physical and psychological 
dependence and addiction, provider knowledge, confidence, and competency regarding these 
issues is critical. A longitudinal study conducted on medical students across four different 
training programs in New Zealand illustrated an increase in competence (knowledge and skills) 
as training progressed, but a notable decrease in students’ subjective perceptions of adequacy and 
self-efficacy in managing issues related to substance abuse, with fewer medical students 
expressing an interest in working with patients with addiction as training progressed (Cape et al., 
2006). The authors speculated that this may be related to increased awareness of the complexity 
of treating substance use disorders, or due to having more negative experiences and perceptions 
of substance users as “patients to be avoided” over time (Cape et al., 2006). General research on 
physician knowledge and attitudes around substance use and interacting with potential substance 
users suggests highly variable training on these issues, even in more experienced professionals 
(Kelleher, 2007). Education on mental health issues (Ballester et al., 2005) as well as 
interpersonal communication skills, also appears to be highly variable across training programs, 
despite recent attempts to expand these competencies (Berkhof, van Rijssen, Schellart, Anema, 
& van der Beek, 2011). Training interventions for improving psychotropic prescription practices 
in primary care have shown mixed results, with many of them demonstrating short-term 
improvements in provider knowledge, but minimal long-term gains with regards to provider 
confidence (Figueiras, Sastre, & Gestal‐Otero, 2001; Midmer, Kahan, & Marlow, 2006).  
Efforts are continually underway to develop and improve training in psychotropic 
medication management in primary care, particularly as guidelines for best prescribing practices 
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continue to shift, and more psychotropic medications are being managed in this setting. 
However, there are few studies to date detailing the firsthand experiences and subjective 
accounts of emerging medical trainees on handling difficult patient encounters around 
psychotropic/controlled substance issues, such as those encountered with benzodiazepines. This 
information will be particularly valuable in understanding how to continue improving training 
and practice models to best inform and support upcoming generations of medical providers who 
will likely face many new challenges and demands regarding benzodiazepines. The present study 
sought to begin filling this gap by answering the following research question: 
What are the experiences of medical residents with regards to training, supervision, and 
consultation around managing benzodiazepine prescribing dilemmas?  
The primary goal of this research was to identify, through direct accounts from residents, 
preliminary areas where they may require additional training and support.  
Method 
Participants 
Family medicine residents at a medical training program in New England were recruited 
via email to participate in a 30-minute focus group interview (held virtually via Zoom video 
conferencing). Permission was given by the medical institution to contact residents and conduct 
the interview during a portion of regularly scheduled didactic trainings in order to minimize 
additional time demands on residents. Efforts were made to emphasize the voluntary nature of 
participation, and to ensure that training directors (who are in a position of authority/power 
relative to residents) were not aware of who chose to participate, in order to minimize possible 
coercion.  
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In order to be included in the study, participants were required to have provided direct 
care (face-to-face or telehealth) to patients for at least three months, and to have had at least one 
experience in which they were asked to begin, discontinue, or adjust a benzodiazepine 
prescription for a patient. Of the 16 residents contacted, four chose to participate in the focus 
group. Due to the small sample size and the potential for participants to be easily identified by 
training directors (who, as previously discussed, hold relative power over trainees) detailed 
demographic information was not reported for this study. However, variability was observed in 
certain sociodemographic areas (e.g., gender identity, race/ethnicity, prior medical training 
programs). Participants were similar in terms of age and ranged from first-to second-year 
residents. The medical residency program served a number of children and adults across the 
lifespan in traditionally underserved suburban and rural communities. Integrated behavioral 
health services had been established within this program for a number of years, though they were 
in the earlier stages of implementation at certain training sites. The patient population served by 
the participants in this study consisted of predominantly low-income adults of varying racial and 
ethnic backgrounds. High rates of co-occurring mental health and substance use disorders as well 
as co-occurring chronic illnesses (i.e., medically complex cases) were noted. 
Design 
This qualitative study was guided by a phenomenological approach to research 
(Moustakas, 1994), as it sought to understand the lived experiences of medical residents with 
regards to managing patient encounters related to benzodiazepines. This theoretical approach 
emphasizes the gathering of in-depth firsthand accounts as a means of better understanding 
human experiences (Van Manen, 2016). Phenomenological research methods are flexible and 
include participant interviews, narratives, and/or ethnographies (Creswell, 2013).  
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A focus group interview format was selected for data collection due to the efficiency it 
offered with regards to scheduling and engaging multiple participants (Krueger & Casey, 2014). 
In recent decades, focus groups have become a popular tool for collecting data on consumer 
opinions and preferences in the field of marketing research (Morgan, 1998). However, their use 
in social science research dates back to the early 1940s, when Paul Lazarsfeld and Robert Merton 
developed this method as a means of identifying “salient dimensions of complex social stimuli as 
a precursor to further quantitative tests” (Onwuegbuzie, Dickinson, Leech, & Zoran, 2009, p. 2). 
Focus groups may appear less intimidating to many participants than individual interviews 
(Krueger & Casey, 2014), and the social component is believed to increase feelings of 
connectedness (Peters, 1993) and encourage more sharing from each participant (Vaughn, 
Schumm, & Sinagub, 1996), producing a somewhat synergistic effect (Dilshad & Latif, 2013). 
Rich data may also emerge from the patterns of social interactions that ensue within the group 
(Onwuegbuzie et al., 2009) and participants may be more apt to offer suggestions for 
improvements in programs and services via group format (Duggleby, 2005). The optimal number 
of participants in a focus group varies. Krueger and Casey assert that five to eight participants is 
ideal for non-marketing research topics, and caution against more than 10 individuals, as this 
tends to limit each person’s contributions to the discussion. However, the authors also discuss the 
increasing popularity of mini focus groups consisting of three to four participants, which increase 
the probability of in-depth contributions from all members, though the overall range of 
experiences represented in the group can be somewhat limited in a smaller sample (Krueger & 
Casey, 2014).  
 
 




A semi-structured interview protocol that I developed was reviewed by medical training 
directors for clarity and appropriateness of wording. Questions were primarily open-ended in 
order to encourage participants to speak broadly of their experiences and engage in group 
discussion, and I provided more specific probes as needed when moderating the focus group 
discussion. 
Interview Questions. The following open-ended interview questions and probes were  
used with focus group participants: 
1. Research suggests that decision making around benzodiazepines can be especially 
difficult for primary care providers (PCPs), particularly when providers and patients 
do not agree. Tell me about a time you were asked to begin, end, or adjust a 
benzodiazepine prescription by a patient. You can focus on one memorable incident 
or provide general details observed across multiple encounters if that’s easier. 
a. What was your ultimate decision (e.g., prescribing, not prescribing, etc.)? 
b. How comfortable/confident did you feel about your decision?  
c. What made the decision difficult/easy? 
d. Did you have any previous experience navigating these interactions? 
e. What potential communication difficulties (if any) did you sense between you 
and the patient? 
2. Were you able to seek supervision/consultation as needed?  If so, how 
beneficial/influential was it in supporting you and your decision-making process? 
3. In what ways do you feel your medical training prepared (or didn’t prepare) you to 
navigate this interaction?  
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4. What recommendations (if any) would you give to training programs in order to 
better support the needs of trainees? 
5. In what ways do you think behavioral health clinicians (BHCs) may be able to better 
help with these dilemmas moving forward (if at all)?  
Procedure 
The steps of the process I used for conducting the focus group interview were as follows. 
Participants were emailed a copy of the informed consent form, and it was reviewed in detail at 
the beginning of the scheduled video meeting. Informed consent was obtained orally from all 
participants before officially beginning the focus group interview. Participants were encouraged 
to find a private location within their respective meeting spaces to ensure the confidentiality of 
everyone in the group. In order to ensure maximum information security over video, a  
HIPAA-compliant Zoom account was used to host the meeting. Though no protected health 
information (PHI), as defined under the Health Insurance Portability and Accountability Act 
(HIPAA), was shared during the focus group, this type of Zoom account offers higher overall 
security and encryption standards. The interview was audio-recorded using a handheld digital 
voice recorder. Raw data was transcribed directly from the device and reviewed for accuracy 
immediately following the interview, and it was deleted from the device following my written 
transcription. The written transcript was stored as a password protected document on a password 
protected computer and was deleted following final data analysis. All possible individual 
identifying information (e.g., names) were excluded from the written transcript. I had previously 
engaged in a training experience at the medical institution from which the data was collected. 
Though I had no previous relationship or interactions with any of the participants prior to the 
study, efforts were made to mitigate possible bias by using a separate independent rater (another 
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clinical psychological doctoral student) to analyze data. This rater was given access to the 
written transcript of the focus group interview.  
Results 
Analysis 
Interview data was analyzed in accordance with Braun and Clarke’s (2006) six-step 
thematic analysis framework which provides an atheoretical multiphasic system for analyzing 
qualitative data. Phases One through Three were performed independently by each of the two 
raters and Phases Four through Six were performed as a group. During Phase One, raters became 
familiar with the data set in its entirety. This was done through transcribing the original audio 
recording (in the case of the primary researcher), as well as reading through the written interview 
transcript multiple times until all content was clearly comprehended (by both raters). During 
Phase Two, raters divided the content into discrete data extracts based on distinct ideas or topics 
and began hypothesizing initial codes. A data extract is defined by Braun and Clarke (2006) as: 
“an individual coded chunk of data, which has been identified within, and extracted from, a data 
item” (p. 6). For the purposes of the current study, extracts were drawn from the written focus 
group dialogue and consisted of individual sentences, phrases, or groups of sentences spoken by 
a single participant that introduced new ideas or concepts. During Phase Three, raters began 
searching the list of codes for possible themes. Singular or possibly irrelevant codes (e.g., codes 
that were noted on only one occasion or clear asides that appeared unrelated to interview topics) 
were set aside during this phase. During Phases Four through Six, raters met to review and 
compare candidate themes, discuss and rework any possible discrepancies, and map out and 
refine the final list of themes. A total of 87 data extracts were identified and reviewed for 
themes. By the final stage of analysis, a total of two main themes and six sub-themes had been 
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identified by raters. A visual representation of the final themes, sub-themes, codes, and number 
of data extracts used for each is presented in Table 1. A sample data extract from each sub-theme 
is presented in Table 2. Additionally, each theme is described in detail below. 
Variability in Resources and Supports 
Variability in Resources and Supports was identified as a main overarching theme. This 
theme captured inconsistencies in quantity, quality, and types of resources and supports offered 
to medical residents. Data extracts and codes encompassed training experiences in medical 
school and residency, as well as general institutional and systemic variables (e.g., related to 
insurance companies, the broader field of medicine). Some of these major content areas were 
undoubtedly informed by the structure of the interview questions, which were targeted toward 
training and supports. Sub-themes are discussed below. 
Medical School. Participants all agreed that initiating new benzodiazepine prescriptions  
had been strongly discouraged in their prior medical school training. Exposure to specific 
coursework in substance use and controlled substances (including psychotropic medications) 
appeared to vary across individual programs, though all focus group participants agreed that 
more emphasis was placed on opioids than benzodiazepines in their training. Exposure to 
benzodiazepines was noted to primarily occur during psychiatric rotations and in 
optional/elective courses. When sharing about a specialized substance use course, one participant 
emphasized: “Not every single medical student in my program took it. I think I was the only one 
there, so it’s not like the medical curriculum put me there.” Participants also highlighted 
differences in recommendations across professors with regards to prescribing benzodiazepines 
and opioids. Participants expressed doubt that examples of “success stories” around controlled 
substances shared in academic settings could be easily applied or translated into real-world 
         
  
24 
clinical practice. One participant reported: “I remember thinking, oh that’s great, I’m glad you’ve 
had success stories, but there was only one of those stories for every ten of my failures.” 
Participants agreed that the general cautionary approach to initiating new prescriptions of both 
benzodiazepines and opioids had been a valuable takeaway of their medical training. However, 
they noted a general lack of coursework on “what to do if someone is already on them,” which 
they identified as a repeated area of clinical difficulty throughout the interview. 
Supervision/Consultation. Inconsistencies were also highlighted by the group in the  
areas of supervision (by more experienced medical professionals) and consultation (with 
professionals at similar levels of training). Participants reported frequent opportunities for 
supervision and consultation around prescribing decisions and the ability to seek them out 
whenever needed. However, they emphasized variability in the approaches of supervising 
(attending) physicians with regards to managing benzodiazepines. Intentional efforts to ensure 
that “all providers were on the same page” were identified as areas of need by participants, 
though they also communicated concerns that forcing everyone to adhere to the same guidelines 
could be viewed as “unethical.” The group discussed discrepancies between their relationships 
with patients and those of attending physicians. One participant shared, with regards to 
communicating decisions that may result in patients becoming angry: “It’s a lot easier for the 
person supervising, because they don’t have to deal with it firsthand, and they don’t have any 
kind of emotional attachment or desire to continue maintaining a relationship with the patient.” 
The group identified a desire for increased “empathy” and understanding from supervisors with 
regards to the way benzodiazepine-related decisions may impact the “patient–provider 
relationship.” 
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Institutional/Systemic Protocols. Lack of cohesiveness and uniformity were also  
discussed with regards to larger institutional and systemic resources and protocols. This included 
types of medications approved by insurance companies, logistical challenges related to tracking 
prescriptions in the electronic health record (EHR) system, and broader “differences of opinion 
on this class of medications” spanning the entire medical profession. One participant shared, 
with regards to more general classes of controlled substances, “I feel like there are other 
alternatives that exist, which are better for patients, but because of the financial burden around 
them, hospitals, and I guess the healthcare system itself, discourage them.” Participants 
acknowledged a general inability to change many of these variables, but concrete improvements 
were suggested with regards to tracking and calculating medication doses. Participants reported 
spending a considerable amount of time and effort performing calculations, checking calendars, 
and cross-comparing records to ensure accuracy of patient reports and appropriate pill count 
when responding to refill requests. Logistical fixes around sorting medications differently in the 
EHR system and receiving automated notifications of when refills should be due were 
recommended by the group.  
Patient–Provider Interactions 
 Patient–Provider Interactions was also identified as a main theme. This theme captured 
patient and provider emotions, provider decision-making processes, and other relationship 
variables that were coded from the case examples provided by residents. Several sub-themes 
emerged under the Patient–Provider Interactions theme. The ones determined to be most salient 
through final analysis are discussed below.  
Ambivalence. Consistent with previous research around prescribing dilemmas,  
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ambivalence, tension, and inner conflict were apparent in the participants’ descriptions of 
interactions with patients around benzodiazepines. Interactions were labeled as “challenges” on 
more than one occasion. Emotions such as “dread” and “discomfort” were mentioned in multiple 
examples. A decision was made to include codes related to these emotions under Ambivalence, 
due to their seeming relation to uncertainty around best patient and provider practices. One 
participant shared: “I dread these patients and I wish I didn’t, though sometimes maybe I 
should.” Ambivalence was also coded in the context of balancing risks and benefits of prolonged 
use versus withdrawal. One participant summarized: “Not only are they addictive, but if you stop 
taking them acutely, you can actually die. With opiates [patients] can have very unpleasant 
symptoms…But if you cut someone cold turkey off a benzodiazepine, you can kill them.” 
Ambiguity or uncertainty in case examples with regards to “making the best decision,” and 
phrases such as, “there is no good solution” were also included under this sub-theme. 
Therapeutic Relationship. Another major content area discussed throughout the focus  
group interview related to the “therapeutic relationship” between patient and provider. 
“Negotiation” and “bargaining” were used to describe typical interactions with patients around 
benzodiazepines. Additional variables related to “intent” and “motivation” of both patients and 
providers were discussed throughout. Consistent with previous literature, concerns around being 
“manipulated” by patients with regards to benzodiazepines (e.g., when being asked to refill 
prescriptions early) were also shared by participants. This was discussed at both an individual 
patient–provider level, and in the context of interactions between patients and multiple providers. 
Participants discussed both real and hypothetical scenarios involving patients becoming aware of 
inconsistencies between providers and “playing them off one another,” or “playing the system,” 
in order to get their needs met. Language associated with behavior management, such as 
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“reinforcement,” specifically concerns around “reinforcing that a pill will solve all their 
problems,” were also discussed in the context of provider decisions around whether to comply 
with patient requests for benzodiazepines.   
Additionally, the therapeutic relationship was also emphasized in the context of treatment 
priorities. Participants reported delaying decisions and discussions with patients around tapering 
or switching medications for fear of “damaging” the patient–provider relationship. One 
participant shared their thought process with more complex patients: “Maybe it would be better 
to keep a good therapeutic relationship, so I can keep working on these other issues they have, 
and maybe one day they’ll be more open to the other stuff.” Concerns around possible ruptures 
or threats to the patient–provider relationship were also discussed extensively in the context of 
supervision and other resources and supports. More specifically, participants appeared concerned 
that inconsistencies in the approaches of attending physicians may “confuse” the patient or 
prompt them to “question the judgment” of medical residents (as their primary providers). 
Concerns were also shared by the group around being placed in a position of acting or appearing 
“ingenuine” toward patients when relaying treatment decisions made by supervisors.  
Empathy. Empathy was identified by the raters as an additional substantive content area  
to be included under the Patient–Provider Interactions theme. Phrases such as, “I empathize 
with,” “I understand why,” or “If I were in the patient’s shoes” were coded under this category. 
Participants acknowledged an overall understanding of why benzodiazepines were helpful to and 
desired by patients with regards to managing anxiety, particularly when other behavioral health 
resources may not be accessible. One participant shared: “I understand why some of these 
patients want the benzos. I don’t have anxiety. But from what some of these people describe, if I 
were experiencing these things every day…trying to live my life and do my job, I would be like, 
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‘Please give me these medications, because this is the only way that I’m going to survive.’” With 
regards to potential “manipulation” by patients, one participant acknowledged: “Patients have 
their ways, and it’s understandable. It’s human nature.” 
Participants acknowledged the benefits of behavioral health services over 
benzodiazepines while explaining how this is not always realistic for their patient population. 
“Yes, it’s as effective, if not more effective, than actually taking the pill, because you’re actually 
working through the problem rather than just pushing it down. But I think it’s difficult for them 
time-wise.” Barriers related to time, transportation, and availability of appointments with mental 
health providers were repeatedly described in the context of understanding patient motivations 
and behaviors: “Sometimes it’s just more time efficient on the patient’s end to take a pill versus 
going to a behavioral health appointment that will take them 45 minutes of traveling, an hour. 
They’re busy, and it’s hard for them to take that much time out.” One participant noted: “There 
aren’t that many behavioral health specialists in the area that we can reach out to when that 
appointment need is there, who are actually available.” Comparisons were made with regards to 
other medications in the context of wanting to “hear patients out.” “With most other medical 
illnesses, if there’s a medicine that works, do we take it away from them? What if we say, ‘this 
diabetes medication works great, but we’re taking it away from you now, because you should 
actually be losing weight and eating healthier and exercising?’”  
Discussion 
The purpose of this qualitative study was to gain a preliminary sense of the experiences 
of emerging primary care providers with regards to training, supervision, and consultation 
around prescribing benzodiazepines (and navigating related patient encounters). A small sample 
of current family medicine residents were recruited to participate in a semi-structured focus 
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group interview. Two main themes, Variability in Resources and Supports and Patient–Provider 
Interactions, were identified through thematic analysis.  
Variability in Resources and Supports captured inconsistencies highlighted by 
participants in the domains (sub-themes) of Medical School, Supervision/Consultation, and 
Institutional/Systemic Protocols. With regards to Medical School, participants reported a  
“hands-off” approach to prescribing benzodiazepines and a relative emphasis on opioids in 
course content across all training programs. However, inconsistencies were noted in the 
availability of and requirements for specific coursework in psychotropic medications and 
controlled substances across programs, as well as the specific stances on benzodiazepines held 
by professors within the same teaching institutions. Gaps and inconsistencies between theory and 
practice were also discussed. Specific to Supervision/Consultation, participants noted that 
supervision around benzodiazepines was always available, but that the approaches of supervising 
(attending) physicians varied substantially with regards to benzodiazepines. With regards to 
larger Institutional/Systemic Protocols, participants highlighted irregularities related to insurance 
companies, technology for calculating and tracking medications, and differences in opinion on 
benzodiazepines spanning the entire medical profession.  
 The second main theme, Patient–Provider Interactions, captured the range of thoughts, 
feelings, motivations, decisions, and interpersonal exchanges between patients and providers 
reported by participants. Three sub-themes (Ambivalence, Therapeutic Relationship, and 
Empathy) were identified under this overarching category. Ambivalence (including tension, 
dread, inner conflict, and difficulties balancing risks and benefits) was apparent in participants’ 
descriptions of patient interactions, which was consistent with previous research findings. 
Descriptions of patient interactions in terms of “negotiation” and “manipulation” also resembled 
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findings from previous qualitative studies on prescribing dilemmas around benzodiazepines. 
However, a somewhat unexpected emphasis on the Therapeutic Relationship and Empathy were 
identified in participants’ descriptions of patient interactions and concerns around 
benzodiazepines. 
A possible causal relationship between the two main thematic areas (Variability in 
Resources and Supports and Patient–Provider Interactions) began to emerge from participants’ 
accounts and is mapped out in Figure 1 (using an arrow) as a preliminary hypothesis for further 
research. Specifically, an overarching concern was highlighted by participants regarding the 
ways inconsistencies in resources and supports (particularly in the area of supervision) may 
manifest in patient–provider interactions. Parallels between the patient–provider and  
resident–supervisor relationship were also apparent with regards to empathy. Participants 
identified a desire for increased empathy from attending physicians toward their own empathy 
and efforts to maintain a therapeutic relationship with patients as a primary need. 
Implications for Practice 
Though it was not surprising, in light of previous research findings, that participants 
experienced ambivalence and discomfort in response to prescribing benzodiazepines, it was 
somewhat unexpected that this discomfort was primarily attributed to concern for the 
“therapeutic relationship” between patients and providers (as opposed to ethical, legal, substance 
abuse, and other concerns mentioned in the previous literature). Concern for the therapeutic 
relationship may be more generally pronounced in earlier stages of training and professional 
development and may not be unique to benzodiazepine-related patient encounters. More research 
is warranted in this area. However, findings of this study suggest that, at least with regards to the 
difficult topic of benzodiazepines, emerging medical residents will likely benefit from increased 
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empathy from supervisors and other supports around the ways inconsistent treatment decisions 
may impact the patient–provider relationship. Participants also discussed the logistical 
importance of developing uniform treatment approaches across supervisors and providers and 
increasing the consistency of resources and protocols around managing benzodiazepines. 
However, their accounts suggested that increased understanding and support from supervisors 
may be the most salient (and easiest to address) need at their current level of training. An 
appreciation of the particularly difficult crossroads medical residents occupy with regards to 
benzodiazepines, due to their status as a trainee in a seemingly divided medical field, and their 
concern for providing quality care to patients, will be useful in understanding how to best 
support them during prescribing dilemmas. This may inform the types of supports offered by 
both supervising/attending physicians and behavioral health consultants (BHCs) in integrated 
primary care settings.  
Limitations  
The small sample size represented by the mini focus group (four participants total) is an 
obvious limitation of the present study. Though the small size of the group appeared to 
encourage more in-depth contributions from each participant, it is unclear whether the 
experiences shared by participants would apply to other family medicine residents and emerging 
primary care providers. A larger and more representative sample (spanning several different 
medical schools and residency programs) would be necessary in order to determine whether the 
themes found within this study could be generalized to the broader population of emerging 
medical professionals. Though the focus group interview questions were primarily open-ended, 
the overall research sought to understand training and supervision experiences. This inevitably 
informed some of the codes and final themes determined to be most prevalent and relevant by 
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myself and the additional rater, as a considerable amount of content fell within these areas. 
Nevertheless, more content regarding the patient–provider relationship than anticipated was 
identified in the data, and determined by raters to be a significant theme, regardless of specific 
interview questions. Finally, though a focus group methodology may cultivate more depth within 
a data set (through its discussion format), it may limit the overall range of experiences 
represented across participants as it pulls for more consensus.  
Future Research 
Findings of this initial qualitative study highlighted a number of inconsistencies 
encountered by a group of emerging primary care providers (family medicine residents) with 
regards to medical school coursework, supervision/consultation, and broader systemic resources 
and protocols for managing benzodiazepine prescriptions. Further research (with a much larger 
and representative sample) is warranted in order to assess whether these inconsistencies are 
present in other training settings. Restructuring of existing training models and programs in order 
to increase the uniformity of coursework, supervision approaches, and general treatment 
protocols may be warranted. Additional research into the developmental level of medical trainees 
and related supervision needs and approaches may also be useful, as it is possible that the 
accounts provided by residents in this study (all within their first two years of residency) were 
not unique to the topic of benzodiazepines and represent a more general professional 
development need. Further exploration and development of general models of supervision within 
the field of medicine may be especially helpful. An emphasis on building frameworks for 
conceptualizing the supervisor–supervisee relationship and possible parallel processes between 
this relationship and the patient–provider relationship may be particularly apt. These concepts 
have already been researched and discussed in other disciplines, such as psychology, and may be 
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adapted as useful. Additionally, a larger scale inquiry into the systemic variables that continue to 
divide the field of medicine with regards to benzodiazepines (in terms of pedagogy, practice, and 
opinions) appears critical to understanding why so many seemingly inappropriate prescribing 
practices persist, despite established changes in guidelines.  
Conclusion 
Though this preliminary qualitative study was inherently limited due to its small sample 
size, a potentially salient hypothesis emerged with regards to the experiences of emerging 
primary care professionals (family medicine residents) around managing benzodiazepines. Focus 
group participants began to highlight a possible relationship between inconsistencies in 
coursework, supervision, and larger systemic and institutional protocols, and the nature of 
patient–provider interactions around benzodiazepines. Concerns that inconsistencies in these 
areas (often beyond the control of medical residents) might adversely impact the therapeutic 
relationship, as well as a desire for more empathy from supervisors regarding this concern were 
highlighted. Further research is recommended in order to see if these concerns are shared by 
other emerging professionals. General developmental levels are apt to play a role in how 
providers experience and navigate difficult prescribing decisions and patient interactions (e.g., 
emerging professionals may experience more stress and ambivalence than experienced 
professionals). However, better understanding the concerns of emerging professionals and 
intervening at these earlier stages of training (e.g., medical school and residency) will be a 
critical first step in increasing confidence and cohesion in the next generation of professionals, 
who will be responsible for shaping the future course of benzodiazepine prescribing in primary 
care.  
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Final Themes Identified by Raters Through Thematic Analysis 
_____________________________________________________________________________ 
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 Ambivalence Clinical 
Feeling/Thinking, 
Difficult/Conflict, 


























Sample Data Extracts for Each Sub-Theme 
______________________________________________________________________________ 





   Medical School But not every single medical student in my 
program took it. I think I was the only one 
there, so it’s not like the medical curriculum 
put me there. 
 
 
   Supervision/ 
  Consultation 
 
I think it’s very subjective. Because every time 
we’re supervised, we’re not supervised by the 
same attendee. So their approaches are quite 
different. 
 
   
 Institutional/Systemic 
Protocols 
I feel like there are other alternatives that exist, 
which are better for patients, but because of the 
financial burden around them, hospitals, and I 






 Ambivalence Something that is also very challenging about 
benzodiazepines, is that, not only are they 
addictive, but if you stop taking them acutely, 
you can actually die. 
 
 Therapeutic  
Relationship 
You kind of end up in this constant negotiation 
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general practitioners for managing the potential ethical dilemmas that may ensue in relation to 
prescribing these controlled substances. The proposed study seeks to fill this gap by identifying 
potentially useful areas for further provider training and support. Findings may help inform 
future medical training models and illuminate opportunities for behavioral health clinicians 
(BHCs) in primary care settings to further support medical doctors (and transitively, patients) in 
these complex encounters. Results will be disseminated via upload to Antioch University’s 
digital repository and will be shared with the participating medical institution. The primary 
researcher will be responsible for collecting the data. 
 
12. Describe the proposed participants- age, number, sex, race, or other special characteristics. 
Describe criteria for inclusion and exclusion of participants. Please provide brief justification for 
these criteria. (Up to 500 words) 
 
Participants will include current family medicine residents from two of X’s medical training 
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sites. Five to eight residents from each site (ten to sixteen participants total) will be recruited to 
participate in one of two separate focus group interviews. Participants will be eighteen years of 
age or older and may vary on the basis of sex, gender identity, race, ethnicity, socioeconomic 
status, and prior medical school training. Efforts will be made to sample residents across a range 
of training levels (first, second, and third year). Inclusion criteria for the focus groups will entail: 
1) At least three months of experience providing direct contact to patients through a supervised 
medical residency program, 2) At least one memorable patient encounter related to 
benzodiazepine prescription (e.g., being asked to adjust, begin, or discontinue a benzodiazepine 
medication), 3) A willingness to participate in a group interview/discussion regarding their 
experiences related to this encounter, and 4) A willingness to be video/audio recorded for the 
purpose of the study. Participation will be entirely voluntary and training directors (who hold a 
position of authority/power over trainees) will not be told who does or does not choose to 
participate. 
 
13. Describe how the participants are to be selected and recruited. (Up to 500 words) 
 
Participants will be selected based on their status as a current family medicine resident within the 
X training system. They will be recruited via email. A contact list of current medical residents 
will be obtained from medical/behavioral health training directors (with the institution’s 
permission; see appended document). Recruitment emails will contain a brief description of the 
proposed research, inclusion criteria, and requirements for participation (see appended 
document). Antioch and X site IRB approval confirmation will also be acknowledged in the 
email. Participants will be invited to opt into a focus group interview/discussion during the final 
forty-five minutes of one of their regularly scheduled didactic trainings, which are currently held 
virtually via Zoom. The date of each focus group will be specified at least two weeks in advance, 
and any supervisors/training directors will be asked to leave the video call before the focus 
groups begin so as not! 
  to see (or unduly influence) who does or does not choose to participate. 
 
14. Do you have a prior or current relationship, either personal, professional, and/or financial, 




14a. If yes, describe the situation that presents a potential personal, professional, and/or financial 
conflict of interest in the proposed research study, (e.g., if you are or have been employed at the 
research site, have received compensation from a participating organization, have a personal or 
professional relationship with any participants). 
 
I was a psychology practicum student at one of the X medical residency sites (X Family Practice) 
from August 2017 to August 2018 and had a professional relationship with some of the medical 
residents and training directors at this specific site. I received compensation for my training 
experience at this site through a federal Graduate Psychology Education (GPE) grant (though I 
was not compensated by X directly). 
 
14b. Describe how you will mitigate the bias caused by any  conflicts of interest in your study 
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and how you will protect the participants against real or potential bias (e.g., you will not recruit 
anyone who works directly for you or in your direct team, results will be reported in the 
aggregate so that participants will remain anonymous, any compensation received is independent 
of the study and its results). 
 
There are multiple training sites within the X medical system, and the three-year nature of this 
residency program ensures that the residents with whom I directly worked will have already 
completed their training at the time of this research. I will also have another psychology doctoral 
peer help review qualitative data in order to minimize possible bias related to my personal 
experiences in this setting. 
 
15. Describe the process you will follow to attain informed consent. 
 
Participants will be emailed a copy of the informed consent form for their reference in the initial 
recruitment email. At the beginning of each scheduled focus group interview, the researcher will 
remind participants that the discussion will be video recorded (though participants can choose to 
have their camera turned off if they so desire) and will encourage anyone who is uncomfortable 
with this to leave the call if needed (no questions asked). The researcher will then begin 
recording. The researcher will proceed to go over the informed consent form in detail, providing 
ample space for questions. Those who do not consent will be allowed to leave the call, and oral 
consent from each remaining participant will then be obtained. 
 
16. Describe the proposed procedures, (e.g., interview surveys, questionnaires, experiments, etc). 
in the project. Any proposed experimental activities that are included in evaluation, research, 
development, demonstration, instruction, study, treatments, debriefing, questionnaires, and 
similar projects must be described. USE SIMPLE LANGUAGE, AVOID JARGON, AND 
IDENTIFY ACRONYMS. Please do not insert a copy of your methodology section from your 
proposal. State briefly and concisely the procedures for the project. (500 words) 
 
Focus group participants will be asked about their experiences related to prescribing 
benzodiazepines, potential dilemmas that have emerged, and training, supervision, and 
consultation experiences and needs through a semi-structured qualitative interview developed by 
the researcher (see appended document). Discussion between participants will be encouraged, 
and the researcher will moderate/redirect the group back to main interview questions and probes 
as needed. Focus group interviews will last approximately forty-five minutes total (including 
time allocated to informed consent at the beginning) and will be conducted via Zoom video 
conferencing technology. Discussions will be recorded for later transcription. Interview data will 
be analyzed in accordance with Braun and Clarke’s (2006) six-step thematic analysis approach. 
Interviews will be coded by two independent raters (one of whom will be the primary researcher 
and interviewer, the other of whom will be a peer from the psychology doctoral program). 
 
17. Participants in research may be exposed to the possibility of harm - physiological, 
psychological, and/or social - please provide the following information: (Up to 500 words) 
a. Identify and describe potential risks of harm to participants (including physical, emotional, 
financial, or social harm). 
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Participants might find the process of discussing potentially challenging patient encounters 
around controlled substances (and their own responses as providers) with a researcher from 
another discipline to be a somewhat vulnerable experience. There is a potential risk of emotional 
distress in the form of frustration, embarrassment, shame, regret, or fear of negative judgment. 
Prior experiences, individual personality and coping styles, and previous opportunities to process 
these experiences with trusted supports or supervisors may influence the extent to which 
participants feel equipped to share openly and/or effectively cope with content discussed during 
group interviews, and the researcher should be sensitive to these variables. 
 
b. Identify and describe the anticipated benefits of this research (including direct benefits to 
participants and to society-at-large or others) 
 
This research seeks to identify ways in which medical training models might better support 
emerging primary care providers in addressing a difficult clinical issue. This has implications for 
both provider and patient wellbeing. Participants might also gain some direct benefit from being 
allowed to process and communicate their challenges and concerns around prescribing 
benzodiazepines through a supportive interaction with peers and the researcher. 
 
c. Explain why you believe the risks are so outweighed by the benefits described above as to 
warrant asking participants to accept these risks. Include a discussion of why the research 
method you propose is superior to alternative methods that may entail less risk. 
 
Decision-making around prescribing benzodiazepines is associated with a number of risks, 
complications, and legal concerns. Research suggests that patient encounters around controlled 
substances are particularly stressful and challenging for primary care providers. However, little 
research has been done to delineate how to best support them in navigating the potential ethical 
dilemmas that may ensue. Though participants in this study may be required to display some 
vulnerability in sharing about their difficulties, the data collected will be critical to informing 
future interventions that may improve provider training and support. 
 
d. Explain fully how the rights and welfare of participants at risk will be protected (e.g., 
screening out particularly vulnerable participants, follow-up contact with participants, list of 
referrals, etc.) and what provisions will be made for the case of an adverse incident occurring 
during the study. 
 
Participants will be made aware during informed consent that they can decline to respond to any 
questions (without additional probing by the researcher) if doing so would cause undue 
emotional distress. They will be free to contribute as much or as little as they desire to the group 
discussion. Participants will be free to withdraw from the study at any point without negative 
repercussions (in which case their individual contributions to the discussion will not be included 
in data analysis or reported). Data will be reported in aggregate form so as to protect the 
identities of individual participants. At the end of the group interview, participants will be invited 
to contact the researcher privately to schedule additional individual debriefing time if needed to 
process difficult emotions that may have come up during the discussion. 
 
18. Explain how participants' privacy is addressed by your proposed research. Specify any steps 
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taken to safeguard the anonymity of participants and/or confidentiality of their responses. 
Indicate what personal identifying information will be kept, and procedures for storage and 
ultimate disposal of personal information. Describe how you will de-identify the data or attach 
the signed confidentiality agreement on the attachments tab (scan, if necessary). (Up to 500 
words) 
 
The researcher will conduct virtual focus group interviews in private meeting spaces using 
appropriate accommodations, such as headsets and/or white noise machines if needed to ensure 
individual participant and group confidentiality. Participants will be encouraged to find similarly 
private meeting spaces at their discretion. Participants will be reminded not to share patient 
protected health information (PHI) as specified under the Health Insurance Portability and 
Accountability Act (HIPAA). They will be encouraged to respect the privacy of other group 
members with regards to content shared during the discussion. Interview recordings will be 
transferred to a secure cloud-based storage program (DropBox) on a password protected 
computer directly following interviews. Verbal dialogue from recordings will be transcribed for 
thematic analysis; during this process any major identifying information (and video footage) will 
be removed from interviews. Digital recordings and transcriptions will be kept until final 
research analysis is complete and will be destroyed after this period. For additional 
confidentiality and security purposes, each participant will be assigned a number code. Files and 
data spreadsheets will be labeled using this code only. Any documents linking participant name 
and number codes will be password protected and stored on an additional password protected 
computer. 
 
19. Will audio-visual devices be used for recording participants? Will electrical, mechanical 




If YES, describe the devices and how they will be used:  
 
Zoom interviews will be recorded using the built-in video recording feature. However, individual 
participants may choose to be recorded on an audio-only basis by turning off their video feature 
during the interview. Though residents will be familiar with Zoom prior to the meeting, 
technological assistance will be provided as needed. 
 
20. Type of Review:  
 
Please provide your reasons/justification for the level of review you are requesting. 
Expedited. The proposed research involves the use of interview procedures. Participants are not 
considered a vulnerable population. The research presents no more than minimal risk (some 
possible emotional discomfort) to participants. Additional risk-mitigation and support protocols 
will be enacted to minimize emotional distress. Protocols will be followed to ensure that 
participants cannot be individually identified from interview data and authorities within the 
organization will not be told which individuals choose to participate in the study (to ensure no 
risks related to professional reputation, employment, etc.). My proposal has been approved by 
my committee. The organization from which the research will be collected is in full support of 
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the study and is eager to use findings to improve future training and support programs. 
 
This research has been approved for submission by my advisor and by others as required by my 
program (e.g., my departmental IRB representative, thesis or dissertation committee or course 




21. Informed consent and/or assent statements, if any are used, are to be included with this 
application. If information other than that provided on the informed consent form is provided 
(e.g. a cover letter), attach a copy of such information. If a consent form is not used, or if consent 
is to be presented orally, state your reason for this modification below. *Oral consent is not 
allowed when participants are under age 18. 
 
See appended recruitment email and appended informed consent form 
 
22. If questionnaires, tests, or related research instruments are to be used, then you must attach a 
copy of the instrument at the bottom of this form (unless the instrument is copyrighted material), 
or submit a detailed description (with examples of items) of the research instruments, 
questionnaires, or tests that are to be used in the project. Copies will be retained in the permanent 
IRB files. If you intend to use a copyrighted instrument, please consult with your research 
advisor and your IRB chair. Please clearly name and identify all attached documents when you 
add them on the attachments tab. 
 
See appended document for interview protocol/questions 
 
I have agreed to conduct this project in accordance with Antioch University's policies and 
requirements involving research as outlined in the IRB Manual and supplemental materials. 
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Appendix B: Redacted Letter of Support from Medical Training Site 
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Appendix C: Informed Consent Form 
Study Title: Physician Training and Support in Managing Dilemmas around Benzodiazepine 
Prescribing 
Investigator: Elizabeth Corley, M.S., Clinical Psychology Doctoral Candidate 
Dissertation Chair: X 
_____________________________________________________________________________ 
 
1. The purpose of this study is to investigate the training, supervision, and consultation 
experiences and needs of medical residents with regards to managing difficult patient 
encounters around benzodiazepine prescriptions.  
 
2. Should I choose to participate, I will be asked to engage in an audio recorded thirty-
minute virtual focus group interview. Interview questions will inquire about clinical 
experiences related to benzodiazepine prescription and related supervision, consultation, 
and training. I may decline to answer any questions if doing so would cause undue 
distress. 
 
3. Participation in this study is entirely voluntary. I may refuse to participate or withdraw at 
any time without creating any harmful consequences to myself. My data will not be used 
if I choose to withdraw. I realize that, due to the focus group nature of the study, it may 
be difficult to guarantee that all of my individual contributions to the group are removed 
should I choose to withdraw, but the investigator will make all reasonable efforts to do 
so. 
 
4. Possible risks of this study include: emotional discomfort when discussing difficult 
patient encounters. I may schedule additional debriefing time with the investigator (which 
will not be recorded or included in research data) if needed. 
 
5. I may find the opportunity to communicate and reflect on my experiences to be of some 
direct benefit to my clinical practice. Information I share in the group may directly 
benefit other group members, or indirectly benefit other providers and patients by helping 
to improve medical training models. 
 
6. Personal identifiers will be removed from the final data set, and my de-identified 
information will not be used or distributed for future research. Results will be reported in 
aggregate form, and direct quotes will not be shared unless they are illustrative of general 
themes observed within the larger group and present no risk of individual identification. 
 
7. The investigator may include the data and results of the study in future scholarly 
publications and presentations. The confidentiality agreement, as articulated above, will 
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If you have any questions about the study, you may contact the principal investigator, Elizabeth 
Corley, M.S. at: X or X or the research supervisor, X, at: X or X. 
 
If you have any questions about your rights as a research participant, you may contact Antioch 
University New England’s IRB Chair, X at: X or X or Provost, X at: X or X. 
 
 
I have reviewed this form in its entirety with the investigator, understand the information 
discussed, and consent to participate in this study. 
 
___________________________  ___________________ 
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Appendix D: Recruitment Email 
Dear Resident, 
 
I am a clinical psychology doctoral candidate at Antioch University New England. I am seeking 
participants for my dissertation research. My IRB-approved study will examine the training, 
supervision, and consultation experiences and needs of medical residents with regards to 
managing difficult patient encounters around benzodiazepine prescriptions.  
 
To participate in this research: 
 
1. You must have at least three months of experience providing direct contact to patients 
(telehealth counts). 
2. You must have experienced at least one patient encounter related to benzodiazepine 




1. A one-time commitment of thirty minutes (which will begin during regularly scheduled 
didactics time) for a Zoom focus group interview. 
2. A willingness to have the interview audio recorded. 
3. Group discussion of clinical experiences related to benzodiazepine prescription and 
related supervision, consultation, and training. 
 
The focus group will be held during the final portion of didactics on X between X and X. To 
participate, all you need to do is stay on the Zoom call as usual (though you are welcome to leave 
if you are not qualified or do not wish to participate). Training directors will end normal 
didactics 15 minutes early and will leave the call so as not to see who chooses to participate. All 
individual identifying information will be kept confidential. 
 
Participants will have an opportunity to provide valuable data that may inform future training 
models. More information can be viewed in the informed consent form attached below. 
 
If you plan on attending, please send me a quick email so we know how many people to expect.  
 
Thank you for your consideration! 
Elizabeth Corley, M.S. 
 
 
 
 
 
